CJC-1295 NO DAC
$
169 AUD
Product Info
CJC-1295 (No DAC) is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH) used in laboratory and biochemical research. Unlike DAC-modified variants, the No DAC form has a shorter active profile, making it suitable for studies examining pulsatile growth hormone signalling and receptor interaction. It is commonly utilised in controlled research settings focused on endocrine pathways, hormone regulation, and peptide–receptor dynamics. This compound is supplied strictly for research purposes only and is not intended for human or veterinary use.
Buy 3 and save 15%
Buy 5 and save 20%
Categories
Bacteriostatic Water
AOD
Cagrilintide
Cagrilintide + Semaglutide
Retatrutide
Semaglutide
Tirzepatide
SLU PP 332
MOTS C
BPC 157
bpc-157-tb-500
Description
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
CJC-1295 without DAC is a 30-amino acid tetrasubstituted GHRH analog designed to stimulate endogenous growth hormone secretion with intermediate half-life compared to both native GHRH and DAC-conjugated variants. The peptide provides sustained GHRH effects with dosing intervals of 2-3 times weekly. CJC-1295 no DAC is extensively studied for its potential in supporting growth hormone production, lean mass development, and metabolic function with balanced dosing frequency and GH axis stimulation. Research indicates the peptide activates GHRH receptor pathways, promoting endogenous growth hormone release with sustained biological activity lasting 24-30 hours per injection. CJC-1295 no DAC represents a valuable research tool for investigating intermediate-duration growth hormone signaling, metabolic adaptation, and therapeutic approaches to GH deficiency and age-related metabolic decline.
Overview
CJC-1295 without DAC is a 30-amino acid tetrasubstituted GHRH analog designed to stimulate endogenous growth hormone secretion with intermediate half-life compared to both native GHRH and DAC-conjugated variants. The peptide provides sustained GHRH effects with dosing intervals of 2-3 times weekly. CJC-1295 no DAC is extensively studied for its potential in supporting growth hormone production, lean mass development, and metabolic function with balanced dosing frequency and GH axis stimulation. Research indicates the peptide activates GHRH receptor pathways, promoting endogenous growth hormone release with sustained biological activity lasting 24-30 hours per injection. CJC-1295 no DAC represents a valuable research tool for investigating intermediate-duration growth hormone signaling, metabolic adaptation, and therapeutic approaches to GH deficiency and age-related metabolic decline.
Biochemical Characteristics
CJC-1295 no DAC is a 30-amino acid GHRH analog with four amino acid modifications (tetrasubstituted), with molecular weight approximately 3,645 Da. The peptide lacks the drug affinity complex (DAC) modification, providing intermediate biological half-life between native GHRH and DAC-conjugated variants. The peptide is water-soluble and demonstrates excellent stability across physiological pH ranges (6.5–8.0). CJC-1295 no DAC exhibits extended biological half-life of approximately 24-30 hours due to amino acid substitutions providing resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other peptidases. Cellular uptake occurs through GHRH receptor binding on pituitary somatotroph cells. The peptide distributes throughout pituitary tissue where growth hormone regulation occurs.
Biochemical Characteristics
CJC-1295 no DAC is a 30-amino acid GHRH analog with four amino acid modifications (tetrasubstituted), with molecular weight approximately 3,645 Da. The peptide lacks the drug affinity complex (DAC) modification, providing intermediate biological half-life between native GHRH and DAC-conjugated variants. The peptide is water-soluble and demonstrates excellent stability across physiological pH ranges (6.5–8.0). CJC-1295 no DAC exhibits extended biological half-life of approximately 24-30 hours due to amino acid substitutions providing resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other peptidases. Cellular uptake occurs through GHRH receptor binding on pituitary somatotroph cells. The peptide distributes throughout pituitary tissue where growth hormone regulation occurs.
Research Applications
Growth Hormone Stimulation Investigation of CJC-1295 no DAC-induced enhancement of endogenous growth hormone release with intermediate duration. Lean Mass Development Assessment of GH-dependent increase in muscle protein synthesis and lean body mass accumulation. Metabolic Rate Enhancement Study of improvements in metabolic rate, energy expenditure, and metabolic flexibility. Body Composition Improvement Investigation of improvements in lean-to-fat mass ratio and reduction in adiposity. Age-Related GH Decline Assessment of restoration of GH secretion in aging models and potential benefits in age-related somatopause. Physical Performance & Recovery Study of improvements in strength, power output, and exercise capacity through GH enhancement. Bone Density Support Investigation of support for bone remodeling and improvement in bone mineral density.
Research Applications
Growth Hormone Stimulation Investigation of CJC-1295 no DAC-induced enhancement of endogenous growth hormone release with intermediate duration. Lean Mass Development Assessment of GH-dependent increase in muscle protein synthesis and lean body mass accumulation. Metabolic Rate Enhancement Study of improvements in metabolic rate, energy expenditure, and metabolic flexibility. Body Composition Improvement Investigation of improvements in lean-to-fat mass ratio and reduction in adiposity. Age-Related GH Decline Assessment of restoration of GH secretion in aging models and potential benefits in age-related somatopause. Physical Performance & Recovery Study of improvements in strength, power output, and exercise capacity through GH enhancement. Bone Density Support Investigation of support for bone remodeling and improvement in bone mineral density.
Pathway / Mechanistic Context
GHRH Receptor Activation CJC-1295 no DAC binds and activates growth hormone-releasing hormone (GHRH) receptors on anterior pituitary somatotroph cells, triggering cAMP-dependent signaling cascades that enhance growth hormone synthesis and secretion. Growth Hormone Release GHRH receptor activation promotes GH synthesis in somatotroph cells and triggers pulsatile exocytosis of growth hormone into systemic circulation with physiological secretion patterns. DPP-4 Resistance The tetrasubstituted amino acid modifications of CJC-1295 no DAC provide resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, extending half-life compared to native GHRH while avoiding need for DAC conjugation. IGF-1 Production Growth hormone released through CJC-1295 no DAC stimulation acts on hepatic and peripheral tissues to enhance insulin-like growth factor-1 production, mediating metabolic and anabolic effects. Lipolysis & Fat Mobilization GH released through CJC-1295 no DAC stimulation enhances lipolysis in adipose tissue through hormone-sensitive lipase activation, promoting fat mobilization and utilization. Somatostatin Feedback Regulation CJC-1295 no DAC-induced GH release provides negative feedback that modulates somatostatin (growth hormone-inhibiting hormone) secretion, maintaining homeostatic control of GH axis function.
Pathway / Mechanistic Context
GHRH Receptor Activation CJC-1295 no DAC binds and activates growth hormone-releasing hormone (GHRH) receptors on anterior pituitary somatotroph cells, triggering cAMP-dependent signaling cascades that enhance growth hormone synthesis and secretion. Growth Hormone Release GHRH receptor activation promotes GH synthesis in somatotroph cells and triggers pulsatile exocytosis of growth hormone into systemic circulation with physiological secretion patterns. DPP-4 Resistance The tetrasubstituted amino acid modifications of CJC-1295 no DAC provide resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, extending half-life compared to native GHRH while avoiding need for DAC conjugation. IGF-1 Production Growth hormone released through CJC-1295 no DAC stimulation acts on hepatic and peripheral tissues to enhance insulin-like growth factor-1 production, mediating metabolic and anabolic effects. Lipolysis & Fat Mobilization GH released through CJC-1295 no DAC stimulation enhances lipolysis in adipose tissue through hormone-sensitive lipase activation, promoting fat mobilization and utilization. Somatostatin Feedback Regulation CJC-1295 no DAC-induced GH release provides negative feedback that modulates somatostatin (growth hormone-inhibiting hormone) secretion, maintaining homeostatic control of GH axis function.
Preclinical Research Summary
CJC-1295 no DAC is supplied as sterile aqueous solution or lyophilized powder at concentrations of 1–10 mg/mL. Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC purity verification (≥95%), HPLC-MS molecular confirmation with tetrasubstituted amino acid verification, amino acid analysis, and microbial sterility/endotoxin testing. Bioassay verification of GHRH receptor agonist activity and GH-stimulatory effects available upon request. Certificate of Analysis provided with each lot.
Preclinical Research Summary
CJC-1295 no DAC is supplied as sterile aqueous solution or lyophilized powder at concentrations of 1–10 mg/mL. Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC purity verification (≥95%), HPLC-MS molecular confirmation with tetrasubstituted amino acid verification, amino acid analysis, and microbial sterility/endotoxin testing. Bioassay verification of GHRH receptor agonist activity and GH-stimulatory effects available upon request. Certificate of Analysis provided with each lot.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
© Standard BioLabs. All rights reserved.